Trusted Resource for Clinical Trials, Protocols & Progress
Adherence and Compliance Studies in Phase 4 Clinical Trials: Real-World Challenges and Strategies Improving Patient Adherence and Compliance Through Phase 4 Research Why Adherence Matters Post-Approval Clinical trial results often assume optimal patient behavior. However, in the real world, the true impact of a drug depends on whether patients take it consistently and correctly. Non-adherence…
Post-Approval Commitments and Phase 4 Study Planning After Phase 3 Trials: A Complete Guide How to Plan Post-Marketing Studies and Fulfill Regulatory Commitments After Phase 3 Trials What Happens After Phase 3 Approval? Approval after successful Phase 3 trials isn’t the end—it’s the beginning of a new chapter in clinical development. Regulatory agencies may grant…
Sample Size Calculation for Phase 2 Trials How to Calculate Sample Size for Phase 2 Clinical Trials Introduction Determining the appropriate sample size in a Phase 2 clinical trial is a critical step that directly affects the trial’s ability to detect meaningful treatment effects, avoid underpowered results, and prevent unnecessary exposure of patients to experimental…
Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment Designing Biosimilar Phase 1 Trials: PK, PD, and Immunogenicity Considerations Introduction Biosimilars—biologic products that are highly similar to an approved reference product—must undergo rigorous evaluation to demonstrate similarity in structure, function, and clinical performance. Phase 1 clinical trials are a cornerstone of biosimilar development and…
Read More “Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment” »
Economic Outcomes and Cost-Effectiveness in Phase 4 Clinical Trials Measuring Cost-Effectiveness and Economic Value in Phase 4 Research Introduction: Why Economic Data Matters in Phase 4 Once a drug enters the market, its clinical benefit must translate into real-world value—not only in health outcomes but also in terms of cost and resource use. That’s where…
Read More “Economic Outcomes and Cost-Effectiveness in Phase 4 Clinical Trials” »
Recruitment and Retention Strategies in Phase 2 Effective Strategies for Patient Recruitment and Retention in Phase 2 Clinical Trials Introduction Phase 2 clinical trials are critical for evaluating a drug’s efficacy, refining dosage, and identifying early safety signals. Yet, one of the most common reasons for delays and failures in Phase 2 is poor patient…
Read More “Recruitment and Retention Strategies in Phase 2” »
Labeling Negotiations and Risk Communication After Phase 3 Trials: Process, Stakeholders, and Best Practices How Drug Labeling and Risk Communication Are Finalized After Phase 3 Trials Why Labeling and Risk Communication Matter Post Phase 3 After a Phase 3 trial concludes and a regulatory submission is underway, a crucial next step is product labeling. The…
Early Stopping Rules in Phase 1 Trials: Safety, PK, and Futility Criteria Understanding When to Stop: Defining Early Termination Criteria in Phase 1 Trials Introduction Phase 1 clinical trials are designed to explore safety, pharmacokinetics (PK), and tolerability of a new investigational drug. Given the first-in-human exposure and potential unknown risks, early stopping rules are…
Read More “Early Stopping Rules in Phase 1 Trials: Safety, PK, and Futility Criteria” »
Phase 4 Trials in Vaccine Safety Monitoring: Ensuring Public Trust Through Real-World Surveillance How Phase 4 Clinical Trials Safeguard Vaccine Safety After Approval Introduction: Why Vaccine Safety Monitoring Doesn’t End at Approval Vaccines are among the most effective public health tools, yet they are administered to healthy populations—including children, the elderly, and immunocompromised individuals. This…
Real-World Data (RWD) Integration into Phase 2 Design and Interpretation Integrating Real-World Data (RWD) into Phase 2 Trial Design and Interpretation Introduction As the clinical research landscape evolves, the role of Real-World Data (RWD) is expanding beyond post-marketing surveillance into earlier stages of development—including Phase 2 trials. RWD sources like electronic health records, insurance claims,…
Read More “Real-World Data (RWD) Integration into Phase 2 Design and Interpretation” »
